Cargando…

Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial

BACKGROUND AND OBJECTIVE: Osteonecrosis of the femoral head (ONFH) is a devastating disease, and there is some evidence that extracorporeal shock wave therapy (ESWT) and intra-articular platelet-rich plasma (PRP) injection might alleviate pain and improve joint function in individuals with ONFH. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Luan, Shuo, Wang, Shaoling, Lin, Caina, Fan, Shengnuo, Liu, Cuicui, Ma, Chao, Wu, Shaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828080/
https://www.ncbi.nlm.nih.gov/pubmed/35153512
http://dx.doi.org/10.2147/JPR.S347961
_version_ 1784647781920538624
author Luan, Shuo
Wang, Shaoling
Lin, Caina
Fan, Shengnuo
Liu, Cuicui
Ma, Chao
Wu, Shaoling
author_facet Luan, Shuo
Wang, Shaoling
Lin, Caina
Fan, Shengnuo
Liu, Cuicui
Ma, Chao
Wu, Shaoling
author_sort Luan, Shuo
collection PubMed
description BACKGROUND AND OBJECTIVE: Osteonecrosis of the femoral head (ONFH) is a devastating disease, and there is some evidence that extracorporeal shock wave therapy (ESWT) and intra-articular platelet-rich plasma (PRP) injection might alleviate pain and improve joint function in individuals with ONFH. The objective of this study was to compare the effectiveness and safety of PRP and ESWT in symptomatic ONFH patients. METHODS: A total of 60 patients aged 40–79 with unilateral ONFH at Association Research Circulation Osseous (ARCO) stages I, II, and III were randomly assigned to the PRP (N=30) or the ESWT group (N=30). Four treatment sessions were provided in both groups. Assessments were performed at baseline, and 1-, 3-, 6-, and 12-month. Primary outcomes were measured by the visual analogue scale (VAS), and pressure pain thresholds (PPTs). Secondary outcomes were assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Harris Hip Score (HHS), and magnetic resonance imaging (MRI). The linear mixed-model analysis was used to evaluate the differences between groups and within groups and the “group by time” interaction effects. RESULTS: There were significant differences between groups in terms of changes over time for VAS, PPTs, WOMAC, and HHS since 3-month and maintained up to 12-month (P<0.05, except for PPTs at 12-month). The simple main effects showed that the patients in PRP group had greater improvements in VAS (mean difference = −0.82, 95% CI [−1.39, −0.25], P=0.005), WOMAC (mean difference = −4.19, 95% CI [−7.00, −1.37], P=0.004), and HHS (mean difference = 5.28, 95% CI [1.94, 8.62], P=0.002). No related adverse events were reported. CONCLUSION: This study supported the effectiveness and safety of both the PRP injection and ESWT in treating ONFH patients. For symptomatic patients with ONFH, intra-articular PRP injection appeared superior to ESWT in pain relief and functional improvement.
format Online
Article
Text
id pubmed-8828080
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88280802022-02-11 Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial Luan, Shuo Wang, Shaoling Lin, Caina Fan, Shengnuo Liu, Cuicui Ma, Chao Wu, Shaoling J Pain Res Original Research BACKGROUND AND OBJECTIVE: Osteonecrosis of the femoral head (ONFH) is a devastating disease, and there is some evidence that extracorporeal shock wave therapy (ESWT) and intra-articular platelet-rich plasma (PRP) injection might alleviate pain and improve joint function in individuals with ONFH. The objective of this study was to compare the effectiveness and safety of PRP and ESWT in symptomatic ONFH patients. METHODS: A total of 60 patients aged 40–79 with unilateral ONFH at Association Research Circulation Osseous (ARCO) stages I, II, and III were randomly assigned to the PRP (N=30) or the ESWT group (N=30). Four treatment sessions were provided in both groups. Assessments were performed at baseline, and 1-, 3-, 6-, and 12-month. Primary outcomes were measured by the visual analogue scale (VAS), and pressure pain thresholds (PPTs). Secondary outcomes were assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Harris Hip Score (HHS), and magnetic resonance imaging (MRI). The linear mixed-model analysis was used to evaluate the differences between groups and within groups and the “group by time” interaction effects. RESULTS: There were significant differences between groups in terms of changes over time for VAS, PPTs, WOMAC, and HHS since 3-month and maintained up to 12-month (P<0.05, except for PPTs at 12-month). The simple main effects showed that the patients in PRP group had greater improvements in VAS (mean difference = −0.82, 95% CI [−1.39, −0.25], P=0.005), WOMAC (mean difference = −4.19, 95% CI [−7.00, −1.37], P=0.004), and HHS (mean difference = 5.28, 95% CI [1.94, 8.62], P=0.002). No related adverse events were reported. CONCLUSION: This study supported the effectiveness and safety of both the PRP injection and ESWT in treating ONFH patients. For symptomatic patients with ONFH, intra-articular PRP injection appeared superior to ESWT in pain relief and functional improvement. Dove 2022-02-05 /pmc/articles/PMC8828080/ /pubmed/35153512 http://dx.doi.org/10.2147/JPR.S347961 Text en © 2022 Luan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Luan, Shuo
Wang, Shaoling
Lin, Caina
Fan, Shengnuo
Liu, Cuicui
Ma, Chao
Wu, Shaoling
Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title_full Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title_fullStr Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title_full_unstemmed Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title_short Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
title_sort comparisons of ultrasound-guided platelet-rich plasma intra-articular injection and extracorporeal shock wave therapy in treating arco i–iii symptomatic non-traumatic femoral head necrosis: a randomized controlled clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828080/
https://www.ncbi.nlm.nih.gov/pubmed/35153512
http://dx.doi.org/10.2147/JPR.S347961
work_keys_str_mv AT luanshuo comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT wangshaoling comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT lincaina comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT fanshengnuo comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT liucuicui comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT machao comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial
AT wushaoling comparisonsofultrasoundguidedplateletrichplasmaintraarticularinjectionandextracorporealshockwavetherapyintreatingarcoiiiisymptomaticnontraumaticfemoralheadnecrosisarandomizedcontrolledclinicaltrial